Trials Sponsors Conditions Drugs Pricing

Conditions

Multiple Myeloma

Keywords

Patient ExperienceTreatment PreferenceQualitative StudyPatient Interviews

Outcome Measures

Primary Outcomes (1)

Patient Experience and Preference
The interview will explore the experiences of people receiving treatment for multiple myeloma and understand what matters most to them when making treatment decisions.
30-60 minutes

Secondary Outcomes (1)

Treatment and Preference Differences
30-60 minutes

Study Arms (1)

Patient Interviews

Participants will be asked to take part in a 30-60 minute interview to understand their treatment preferences. Members of the research team will conduct this either in the clinic or over the phone, as per patient preference.

Other: Patient Interview

Interventions

Patient InterviewOther

Participants will be asked to take part in a 30-60 minute interview to understand their treatment experiences and preferences.

Patient Interviews

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients with multiple myeloma who have received at least five lines of treatment.

You may qualify if:

Participants with confirmed MM (per standard disease specific diagnostic criteria)

Sponsors & Collaborators

CellCentric Ltd.
Industrycollaborator
The Christie NHS Foundation Trust
Otherlead

Study Sites (1)

The Christie NHS Foundation Trust

Manchester, Greater Manchester, M20 4BX, United Kingdom

Related Publications (1)

Perry MB, Lochhead Devaraj R, Law K, Ashby F, Taylor S. iPREFER: Patients' Experiences and Preference of Treatment for Multiple Myeloma Following Multiple Lines of Treatment - A Qualitative Study. Patient Prefer Adherence. 2026 Apr 28;20:576524. doi: 10.2147/PPA.S576524. eCollection 2026.
PMID: 42080199DERIVED

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System Diseases

Study Officials

Sally Taylor, PhD
The Christie NHS Foundation Trust
PRINCIPAL INVESTIGATOR

Enrollment

9 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: OTHER
Time Perspective: CROSS SECTIONAL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

March 14, 2024

First Posted

March 21, 2024

Study Start

April 5, 2024

Actual (reported)

PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Patient Interviews

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Patient Interviews

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations